|3 Months Ended|
Mar. 31, 2019
Revenues disaggregated by category were as follows (in thousands):
The following table summarizes revenues from each of our customers who individually accounted for 10% or more of our total revenues (as a percentage of total revenues):
Our first and only FDA approved product, TAVALISSE®, was approved by the U.S. FDA in April 2018. We commenced commercial sale of TAVALISSE in the U.S. in May 2018.
In addition to the distribution agreements with our customers, the SDs, we also enter into arrangements with specialty pharmacy providers, in-office dispensing providers, group purchasing organizations, and government entities that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts with respect to the purchase of our products which reduced our gross product sales. Also refer to Revenue Recognition policy discussion in Note 3.
The following tables summarize activity in each of the product revenue allowance and reserve categories for the three months ended March 31, 2019 (in thousands):
The above provisions, which included the provision for current period sales of $1.7 million, are included as part of Other Accrued Liabilities in the balance sheet. The remaining $202,000 in provision related to current period sales is recorded as reduction of accounts receivable and prepaid and other current assets in the balance sheet.
The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.
Reference 1: http://www.xbrl.org/2003/role/presentationRef